Wet Age-related Macular Degeneration (Wet AMD) Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight

“Wet Age-related Macular Degeneration (Wet AMD) Pipeline Insight, 2025” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Wet AMD Market.

The Wet AMD Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Wet AMD Pipeline Report:

• Companies across the globe are diligently working toward developing novel Wet AMD treatment therapies with a considerable amount of success over the years.

• Wet AMD companies working in the treatment market are Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, Roche, Opthea, and others, are developing therapies for the Wet AMD treatment.

• Emerging Wet AMD therapies in the different phases of clinical trials are- KSI-501, RGX-314 (ABBV-RGX-314), CG-P5 peptide, NT-101, and others are expected to have a significant impact on the Wet AMD market in the coming years.

• In April 2026, Regeneron Pharmaceuticals, Inc. announced that the US FDA approved extending dosing intervals for EYLEA HD (aflibercept) up to every 20 weeks in wet AMD and Diabetic Macular Edema (DME) patients after one year of response, supported by 2-year data from the PULSAR and PHOTON trials showing sustained efficacy and safety.

• In November 2025, Kodiak Sciences announced completion of enrollment (~690 patients) in the Phase III DAYBREAK study evaluating tarcocimab and KSI-501 in treatment-naive Wet AMD, with the 48-week primary endpoint expected in August 2026 and topline data anticipated in Q3 2026.

• In October 2025, REGENXBIO announced the completion of enrollment in the pivotal ATMOSPHERE and ASCENT studies evaluating surabgene lomparvovec (ABBV-RGX-314) for wet AMD using subretinal delivery.

Wet Age-related Macular Degeneration (Wet AMD) Overview

Wet Age-related Macular Degeneration (Wet AMD) is an advanced form of Age-related Macular Degeneration, occurring when abnormal blood vessels grow beneath the retina and leak fluid or blood, leading to rapid and severe vision loss. It can progress quickly, with symptoms such as blurred or distorted central vision, dark spots, and difficulty recognizing faces, especially in later stages. Wet AMD is mainly caused by abnormal vascular growth driven by factors like aging and oxidative stress. While there is no cure, treatment options-including intravitreal anti-VEGF therapy, sustained delivery systems, and lifestyle changes-can help manage symptoms and improve quality of life.

Get a Free Sample PDF Report to know more about Wet Age-related Macular Degeneration (Wet AMD) Pipeline Therapeutic Assessment

Emerging Wet AMD Drugs Under Different Phases of Clinical Development Include:

• Aflibercept (EYLEA HD): Regeneron Pharmaceuticals/Bayer

• Ranibizumab (LUCENTIS): Genentech

• Faricimab (VABYSMO): Genentech

• KSI-501: Kodiak Sciences

• RGX-314 (ABBV-RGX-314): AbbVie/Regenxbio

• CG-P5 peptide: Caregen

• NT-101: NexThera

Wet Age-related Macular Degeneration (Wet AMD) Route of Administration

Wet AMD pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intravitreal injection

• Subretinal injection

• Suprachoroidal injection

• Topical ophthalmic (eye drops)

Wet Age-related Macular Degeneration (Wet AMD) Molecule Type

Wet AMD Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Recombinant Fusion Protein

• Peptide

• Gene therapy (AAV vector)

• Bispecific monoclonal antibody

Wet Age-related Macular Degeneration (Wet AMD) Pipeline Therapeutics Assessment

• Wet AMD Assessment by Product Type

• Wet AMD By Stage and Product Type

• Wet AMD Assessment by Route of Administration

• Wet AMD By Stage and Route of Administration

• Wet AMD Assessment by Molecule Type

• Wet AMD by Stage and Molecule Type

• DelveInsight’s Wet AMD Report covers products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Further Wet AMD product details are provided in the report. Download the Wet AMD pipeline report to learn more about the emerging Wet AMD therapies

• Some of the key companies in the Wet AMD Therapeutics Market include:

• Key companies developing therapies for Wet AMD are – Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, and others.

Wet Age-related Macular Degeneration (Wet AMD) Pipeline Analysis:

The Wet AMD pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Wet AMD with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Wet AMD Treatment.

• Wet AMD key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Wet AMD Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Wet AMD market.

• The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Wet AMD drugs and therapies

Wet Age-related Macular Degeneration (Wet AMD) Pipeline Market Drivers

Rising prevalence of Wet AMD worldwide, particularly among the 85+ population, along with a moderately active drug pipeline and new product combinations targeting durability and reduced injection burden, are some of the important factors that are fueling the Wet AMD Market.

Wet Age-related Macular Degeneration (Wet AMD) Pipeline Market Barriers

However, high treatment burden associated with frequent intravitreal injections, variable patient response despite therapy, limited long-term durability of current anti-VEGF treatments, and delayed diagnosis due to subtle early symptoms are creating obstacles in the Wet AMD Market growth.

Scope of Wet Age-related Macular Degeneration (Wet AMD) Pipeline Drug Insight

• Coverage: Global

• Key Wet AMD Companies: Regeneron Pharmaceuticals, Bayer, Genentech, Kodiak Sciences, AbbVie, Regenxbio, Caregen, NexThera, and others

• Key Wet AMD Therapies: Aflibercept (EYLEA HD), Ranibizumab (LUCENTIS), Faricimab (VABYSMO), KSI-501, RGX-314, CG-P5 peptide, NT-101, and others

• Wet AMD Therapeutic Assessment: Wet AMD current marketed and Wet AMD emerging therapies

• Wet AMD Market Dynamics: Wet AMD market drivers and Wet AMD market barriers

Request for Sample PDF Report for Wet Age-related Macular Degeneration (Wet AMD) Pipeline Assessment and clinical trials

Table of Contents

1. Wet Age-related Macular Degeneration (Wet AMD) Report Introduction

2. Wet Age-related Macular Degeneration (Wet AMD) Executive Summary

3. Wet Age-related Macular Degeneration (Wet AMD) Overview

4. Wet Age-related Macular Degeneration (Wet AMD)- Analytical Perspective In-depth Commercial Assessment

5. Wet Age-related Macular Degeneration (Wet AMD) Pipeline Therapeutics

6. Wet Age-related Macular Degeneration (Wet AMD) Late Stage Products (Phase III)

7. Wet Age-related Macular Degeneration (Wet AMD) Mid Stage Products (Phase II)

8. Wet Age-related Macular Degeneration (Wet AMD) Early Stage Products (Phase I)

9. Wet Age-related Macular Degeneration (Wet AMD) Preclinical Stage Products

10. Wet Age-related Macular Degeneration (Wet AMD) Therapeutics Assessment

11. Wet Age-related Macular Degeneration (Wet AMD) Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Wet Age-related Macular Degeneration (Wet AMD) Key Companies

14. Wet Age-related Macular Degeneration (Wet AMD) Key Products

15. Wet Age-related Macular Degeneration (Wet AMD) Unmet Needs

16. Wet Age-related Macular Degeneration (Wet AMD) Market Drivers and Barriers

17. Wet Age-related Macular Degeneration (Wet AMD) Future Perspectives and Conclusion

18. Wet Age-related Macular Degeneration (Wet AMD) Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/